Dependent variable:
1-Revenues growth per employee (2006-2010):
where revenues are expressed in Million USD.
Independent variables:
1-Ability to deviate in each phase transition in each therapeutic area, where is the number of compounds recorded in December
2009, E the expected number of compounds one, and indicates the clinical phase.
2-The firm's Size: Total Number of Employees (for each firm at t=2010)

3-Herfindahl-Hirschman Index (HHI) (economies of scope):
For each firm is given by 4-Change over time in R&D spread across therapeutic areas:
5-BIO:
Note that: Index will refer to the firm, with
Normalised with respect to: -maximum deviation within therapeutic area -total compounds developed by each firm Note that: DEV-Ph1_MX BIO, RD_TA and Size have been dropped because they were not statistically significant 
